Navigation Links
Mindray Medical International Announces Third Quarter 2007 Results
Date:11/1/2007

Company Achieves Record Revenue Growth of 58.9% Year-over-Year

SHENZHEN, China, Nov. 1 /Xinhua-PRNewswire-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices in China with a rapidly growing international presence, today announced its selected unaudited financial results for the third quarter ended September 30, 2007.

Highlights for Third Quarter 2007

-- Third quarter 2007 net revenues were RMB573.2 million (US$76.5 million),

a 58.9% increase over the third quarter 2006.

-- Net revenues generated in international markets in the third quarter

2007 increased by 52.0% to RMB286.1 million (US$38.2 million) from

RMB188.2 million in the third quarter 2006.

-- Net revenues generated in China in the third quarter of 2007

increased by 66.3% to RMB287.1 million (US$38.3 million) from

RMB172.7 million in the third quarter 2006.

-- Third quarter 2007 non-GAAP net income, as defined below, increased

71.5% year-over-year to RMB172.1 million (US$23.0 million) from

RMB100.4 million in the third quarter 2006. Third quarter 2007 GAAP

net income was RMB154.8 million (US$20.7 million) compared to RMB91.0

million in the third quarter 2006, representing an increase of 70.0%

year-over-year.

-- Third quarter 2007 non-GAAP diluted earnings per share, as defined

below, was RMB1.52 (US$0.20). Third quarter 2007 GAAP diluted earnings

per share was RMB1.37 (US$0.18).

"We are pleased to report another quarter of record growth and solid execution," said Mr. Xu Hang, Mindray's chairman and co-chiefnot be calculated on the same basis of similar measures used by other companies. Readers are cautioned not to view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of GAAP results with non-GAAP results for the three-month periods ended September 30, 2006 and 2007, respectively, in the attached financial statements.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements," including those related to the company's anticipated operating results for 2007, increased medical device spending in China, customer acceptance of company products, continued benefits of R&D spending levels, increased headcounts, growth in the company's business segments and geographies, business execution, growth in medical spending and the factors driving that growth, and international expansion. These statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. It is possible that our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Readers are cautioned that these forward- looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including but not limited to: the expected growth of the medical device market in China and internationally; relevant government policies and regulations relating to the medical device industry; market acceptance of our products; our expectations regarding demand for our products; our ability to expand our production, our sales and distribution network and other aspects of our operations; our ability to stay abreast of market trends and technological advances; our ability to effectively protect our intellectual property rights and not infringe on the intellectual property rights of others; competition in the medical device industry in China and internationally; and general economic and business conditions in the countries in which we operate. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our public filings with the Securities and Exchange Commission.. For a discussion of other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 5 of our annual report on Form 20-F, filed on June 26, 2007. Our results of operations for the third quarter of 2007 and for fiscal year 2007 are not necessarily indicative of our operating results for any future periods. Any projections in this release are based on limited information currently available to us, which is subject to change. Although such projections and the factors influencing them will likely change, we will not necessarily update the information. Such information speaks only as of the date of this release.

This announcement contains translations of certain Renminbi amounts into US dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to US dollars as of and for the quarter ended September 30, 2007 were made at the noon buying rate in the City of New York for cable transfers in Renminbi per US dollar as certified for customs purposes by the Federal Reserve Bank of New York, or the noon buying rate, as of September 28, 2007, which was RMB7.4928 to US$1.00. Mindray makes no representation that the Renminbi or US dollar amounts referred to in this release could have been or could be converted into US dollars or Renminbi, as the case maybe, at any particular rate or at all.

All references to "shares" are to our ordinary shares, which are divided into two classes, Class A and Class B. Each of our American Depositary Shares, which trade on the New York Stock Exchange, represents one Class A ordinary share. The accounting policies underlying the financial information for the segmental reporting are based primarily on statutory accounting requirements in the PRC.

Exhibit 1

MINDRAY MEDICAL INTERNATIONAL LIMITED

CONDENSED CONSOLIDATED BALANCE SHEETS

As at

December 31, As at

2006 September 30, 2007

RMB RMB US$

(derived

from audited

financials) (unaudited)(unaudited)

ASSETS (In thousands) (In thousands)

Current assets:

Cash and cash equivalents 1,709,596 1,318,102 175,916

Restricted cash -- -- --

Short-term investments 13,312 418,498 55,853

Accounts receivable, net 104,679 145,396 19,405

Inventories, net 122,071 199,129 26,576

Value added tax receivables -- -- --

Other receivables 11,774 28,313 3,779

Prepayments and other 19,263 15,924 2,125

Deferred tax assets - current

portion 2,747 2,410 322

Total current assets 1,983,442 2,127,772 283,976

Loans to employees 4,851 4,895 653

Long-term investments 105,573 250,000 33,365

Other assets 2,124 36,781 4,909

Property, plant and equipment,

net 186,980 315,467 42,103

Land use right 2,505 2,405 321

Intangible assets 149,479 135,357 18,065

Goodwill 122,169 122,169 16,305

Total assets 2,557,123 2,994,846 399,697

LIABILITIES AND SHAREHOLDERS'

EQUITY

Current liabilities:

Notes payable 50,625 58,409 7,795

Accounts payable 79,352 98,578 13,156

Customers' deposits 47,007 37,996 5,071

Salaries payables 55,676 59,323 7,917

Other payables 100,082 105,469 14,076

Income taxes payable 11,703 44,433 5,930

Other taxes payable 7,937 8,729 1,165

Total current liabilities 352,382 412,937 55,111

Commitment and contingencies

Minority interests 11 10 1

Deferred tax liabilities, net 21,815 19,583 2,614

21,826 19,593 2,615

Mezzanine equity:

Convertible redeemable

preferred shares -- --

Shareholders' equity:

Ordinary shares 110 111 15

Additional paid-in capital 1,934,937 2,037,217 271,890

Retained earnings 266,833 578,718 77,237

Accumulated other

comprehensive loss (18,965) (53,730) (7,171)

Total shareholders' equity 2,182,915 2,562,316 341,970

Total liabilities and shareholders'

equity 2,557,123 2,994,846 399,697

(1) All translations from Renminbi to US dollars as of and for the

quarter and nine months ended September 30, 2007 were made at the noon

buying rate of the Federal Reserve Bank of New York as of September

28, 2007, which was RMB 7.4928 to US$1.00

Exhibit 2

MINDRAY MEDICAL INTERNATIONAL LIMITED

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Three months ended September 30

2006 2007 2007

RMB RMB US$

(unaudited) (unaudited) (unaudited)

Net revenues

- PRC 172,683 287,144 38,323

- International 188,176 286,092 38,182

Net revenues 360,859 573,236 76,505

Cost of revenues (note 2) (159,758) (257,369) (34,349)

Gross profit 201,101 315,867 42,156

Selling expenses (note 2) (49,467) (83,366) (11,126)

General and administrative expenses

(note 2) (18,237) (21,195) (2,829)

Research and development expenses

(note 2) (36,497) (56,706) (7,568)

Other general expenses 23 (18) (2)

Operating income 96,923 154,582 20,631

Other income, net (1,707) 8,604 1,148

Interest income 2,336 16,755 2,236

Interest expense (48) (37) (5)

Income before income taxes and

minority interests 97,504 179,904 24,010

Provision for income taxes (6,458) (25,137) (3,355)

Minority interests -- 0 0

Net Income 91,046 154,767 20,655

Basic earnings per share 1.07 1.45 0.19

Diluted earnings per share 0.94 1.37 0.18

Shares used in the computation of:

Basic earnings per share 85,276,860 106,586,981 106,586,981

Diluted earnings per share 96,913,296 113,036,660 113,036,660

(2) Share-based compensation charges

incurred during the period related

to:

Cost of revenues 190 411 55

Selling expenses 2,218 4,733 632

General and administrative expenses 4,266 4,154 554

Research and development expenses 2,653 4,040 539

Exhibit 2

MINDRAY MEDICAL INTERNATIONAL LIMITED

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Nine months ended September 30

2006 2007 2007

RMB RMB US$

(unaudited) (unaudited) (unaudited)

Net revenues

- PRC 553,618 774,621 103,382

- International 484,006 782,511 104,435

Net revenues 1,037,625 1,557,132 207,817

Cost of revenues (note 2) (467,088) (689,481) (92,019)

Gross profit 570,537 867,651 115,798

Selling expenses (note 2) (149,442) (212,430) (28,351)

General and administrative expenses

(note 2) (43,102) (65,191) (8,700)

Research and development expenses

(note 2) (103,175) (147,211) (19,647)

Other general expenses 23 (197) (26)

Operating income 274,841 442,622 59,073

Other income, net (1,467) 11,680 1,559

Interest income 8,878 53,711 7,168

Interest expense (327) (63) (8)

Income before income taxes and

minority interests 281,925 507,950 67,792

Provision for income taxes (19,649) (74,294) (9,915)

Minority interests (6,456) 0 0

Net Income 255,820 433,656 57,876

Basic earnings per share 3.17 4.08 0.55

Diluted earnings per share 2.80 3.85 0.51

Shares used in the computation of:

Basic earnings per share 80,777,302 106,171,253 106,171,253

Diluted earnings per share 91,314,023 112,620,932 112,620,932

(2) Share-based compensation charges

incurred during the period related

to:

Cost of revenues 426 1,187 158

Selling expenses 5,555 15,049 2,008

General and administrative expenses 8,749 12,685 1,693

Research and development expenses 4,783 12,025 1,605

Exhibit 3

MINDRAY MEDICAL INTERNATIONAL LIMITED

RECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST

COMPARABLE GAAP MEASURES

Three months ended September 30,

2006 2007 2007

RMB RMB US$

(unaudited) (unaudited) (unaudited)

(In thousands, except share and per

share data)

Non-GAAP net income (note 3) 100,373 172,106 22,970

Non-GAAP net margin 27.8% 30.0% 30.0%

Expense/Amortization of acquired

intangible assets -- (4,707) (628)

Deferred tax impact related to

acquired intangible assets -- 706 94

Share-based compensation (9,327) (13,338) (1,780)

GAAP net income 91,046 154,767 20,655

GAAP net margin 25.2% 27.0% 27.0%

Non-GAAP income per share - basic 1.18 1.61 0.22

Non-GAAP income per share - diluted 1.04 1.52 0.20

GAAP income per share - basic 1.07 1.45 0.19

GAAP income per share - diluted 0.94 1.37 0.18

Shares used in computation of:

Basic earnings per share 85,276,860 106,586,981 106,586,981

Diluted earnings per share 96,913,296 113,036,660 113,036,660

Non-GAAP operating income 106,250 172,627 23,039

Non-GAAP operating margin 29.4% 30.1% 30.1%

Expense/Amortization of acquired

intangible assets -- (4,707) (628)

Share-based compensation (9,327) (13,338) (1,780)

GAAP operating income 96,923 154,582 20,631

GAAP operating margin 26.9% 27.0% 27.0%

Non-GAAP gross profit 201,291 320,985 42,839

Non-GAAP gross margin 55.8% 56.0% 56.0%

Expense/Amortization of acquired

intangible assets -- (4,707) (628)

Share-based compensation (190) (411) (55)

GAAP gross profit 201,101 315,867 42,156

GAAP gross margin 55.7% 55.1% 55.1%

Exhibit 3

MINDRAY MEDICAL INTERNATIONAL LIMITED

RECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST

COMPARABLE GAAP MEASURES

Nine months ended September 30,

2006 2007 2007

RMB RMB US$

(unaudited) (unaudited) (unaudited)

(In thousands, except share and per

share data)

Non-GAAP net income (note 3) 275,332 486,607 64,943

Non-GAAP net margin 26.5% 31.3% 31.3%

Expense/Amortization of acquired

intangible assets -- (14,122) (1,885)

Deferred tax impact related to

acquired intangible assets -- 2,118 283

Share-based compensation (19,513) (40,946) (5,465)

GAAP net income 255,819 433,657 57,876

GAAP net margin 24.7% 27.8% 27.8%

Non-GAAP income per share - basic 3.41 4.58 0.61

Non-GAAP income per share - diluted 3.02 4.32 0.58

GAAP income per share - basic 3.17 4.08 0.55

GAAP income per share - diluted 2.80 3.85 0.51

Shares used in computation of:

Basic earnings per share 80,777,302 106,171,253 106,171,253

Diluted earnings per share 91,314,023 112,620,932 112,620,932

Non-GAAP operating income 294,353 497,690 66,422

Non-GAAP operating margin 28.4% 32.0% 32.0%

Expense/Amortization of acquired

intangible assets -- (14,122) (1,885)

Share-based compensation (19,513) (40,946) (5,465)

GAAP operating income 274,840 442,622 59,073

GAAP operating margin 26.5% 28.4% 28.4%

Non-GAAP gross profit 570,962 882,960 117,841

Non-GAAP gross margin 55.0% 56.7% 56.7%

Expense/Amortization of acquired

intangible assets -- (14,122) (1,885)

Share-based compensation (426) (1,187) (158)

GAAP gross profit 570,536 867,651 115,798

GAAP gross margin 55.0% 55.7% 55.7%

For investor and media inquiries, please contact:

In China:

Investor Relations

Mindray Medical International Limited

Tel: +86-755-2658-2518

Email: IR@Mindray.com

Justin Knapp

Ogilvy Public Relations Worldwide, Beijing

Tel: +86-10-8520-6556

Email:

"In our domestic market, we continue to benefit from rising private healthcare spending, as well as a steady increase in government tenders. These trends reflect the strong growth of China's economy and the government's commitment to investing in rural healthcare infrastructure," added Mr. Li Xiting, Mindray's president and co-chief executive officer. "Internationally, product sales saw healthy growth across all of our geographies, most notably in our European and South American markets. During the quarter we remained focused on building out an extensive international distribution network and further expanded our presence abroad, opening offices in Canada, Brazil, Mexico and the Netherlands."

The company now has 29 sales and service offices in China and 10 internationally.

Financial Results for Third Quarter 2007

Mindray reported net revenues of RMB573.2 million (US$76.5 million) for the third quarter 2007, representing a 58.9% increase from RMB360.9 million in the third quarter 2006.

Net revenues generated in international markets in the third quarter 2007 increased by 52.0% to RMB286.1 million (US$38.2 million) from RMB188.2 million in the third quarter 2006.

Net revenues generated in China in the third quarter 2007 increased by 66.3% to RMB287.1 million (US$38.3 million) from RMB172.7 million in the third quarter 2006.

Performance by Segment

Patient Monitoring Devices: Patient monitoring device segment revenues increased 48.5% to RMB207.1 million (US$27.6 million) from RMB139.5 million in the third quarter 2006. The patient monitoring device segment contributed 36.6% of total :Justin.Knapp@Ogilvy.com">Justin.Knapp@Ogilvy.com

In the United States:

Jeremy Bridgman

Ogilvy Public Relations Worldwide, New York

Tel: +1-212-880-5363

net segment revenues in the third quarter 2007.

Growth in the patient monitoring segment was led by increased brand recognition in international markets as well as a healthier domestic environment compared to the third quarter 2006. The company's high-end BeneView series also experienced strong performance both domestically and internationally.

Diagnostic Laboratory Instruments: Diagnostic laboratory instrument segment revenues increased 64.5% to RMB186.3 million (US$24.9 million) from RMB113.3 million in the third quarter 2006. The diagnostic laboratory instrument segment contributed 33.0% of total net segment revenues in the third quarter 2007.

The diagnostic laboratory instrument segment enjoyed exceptional growth during the third quarter. Domestically, revenues were boosted by increased government spending on rural healthcare development. Expanding international market penetration and demand for new products such as the BS-400 and BC-5500 increased segment growth during the third quarter 2007.

Ultrasound Imaging Systems: Ultrasound imaging system segment revenues increased 66.2% to RMB162.2 million (US$21.7 million) from RMB97.6 million in the third quarter 2006. The ultrasound imaging system segment contributed 28.7% as a percentage of total net segment revenues in the third quarter 2007.

Government tender activity made a significant contribution to ultrasound growth during the third quarter 2007 compared to the same period a year ago. Demand for color ultrasound machines remained strong both domestically and internationally.

The company also plans to launch several products in the fourth quarter of 2007, including the M5, a portable color ultrasound machine, the BS-100, a biochemistry analyzer targeted for rural healthcare clinics in China, the DC-3, a color ultrasound machine, an EX55 and EX65, which are both compact anesthesia machines available domestically upon release and internationally in March 2008 and the BC-5300, a five-part differential hematology analyzer. All of these products will contribute to 2008 sales.

Gross Margins

Third quarter 2007 gross profit was RMB315.9 million (US$42.2 million), a 57.1% increase from RMB201.1 million in the third quarter 2006. The consolidated gross margin for the third quarter 2007 was 55.1% compared to 56.0% in the second quarter 2007. Non-GAAP gross margin, as defined below, was 56.0% in the third quarter 2007 compared to 57.0% in the second quarter 2007, and 56.7% in the first nine months of 2007.

Operating Expenses

Selling expenses for the third quarter 2007 were RMB83.4 million (US$11.1 million), representing 14.5% of total net revenues, compared to 13.7% in the third quarter 2006 and 14.4% in the second quarter 2007. Selling expenses slightly increased as the company opened new offices abroad increasing sales, marketing, and distribution headcount.

General and administrative expenses for the third quarter 2007 were RMB21.2 million (US$2.8 million), representing 3.7% of total revenues, compared to 5.1% in the third quarter 2006 and 3.7% in the second quarter 2007.

Research and development expenses for the third quarter 2007 were RMB56.7 million (US$7.6 million), compared to RMB36.5 million in the third quarter 2006. Research and development expenses were 9.9% of total net revenues, compared to 10.1% in the third quarter 2006 and 8.8% in the second quarter 2007.

Total share-based compensation expenses, which were allocated to cost of goods sold and related operating expenses, were RMB13.3 million (US$1.8 million) in the third quarter 2007, compared to RMB9.3 million (US$1.2 million) in the third quarter 2006 and RMB14.3 million (US$1.9 million) in the second quarter 2007.

Non-GAAP operating profit, as defined below, in the third quarter 2007 was RMB172.6 million (US$23.0 million), representing a 62.4% increase from RMB106.3 million in the third quarter 2006. GAAP operating profit in the third quarter 2007 was RMB154.6 million (US$20.6 million), representing a 59.5% increase from RMB96.9 million in the third quarter 2006. Non-GAAP operating margins were 30.1% in the third quarter 2007, compared to 29.4% in the third quarter 2006 and 32.5% in the second quarter 2007. GAAP operating margins were 27.0% in the third quarter 2007 compared to 26.9% in the third quarter 2006 and 29.1% in the second quarter 2007.

The company noted the increase in non-operating income during the third quarter 2007 was largely due to unrealized marked-to-market gains from foreign exchange appreciation.

Net Income

Third quarter 2007 non-GAAP net income increased 71.5% year-over-year to RMB172.1 million (US$23.0 million) from RMB100.4 million in the third quarter 2006. Third quarter 2007 GAAP net income was RMB154.8 million (US$20.7 million) compared with RMB91.0 million in the third quarter 2006. Non-GAAP net margins were 30.0% in the third quarter 2007, from 27.8% in the third quarter 2006 and 31.1% in the second quarter 2007. GAAP net margins were 27.0% in the third quarter 2007 compared to 25.2% in the third quarter 2006 and 27.9% in the second quarter 2007. Third quarter 2007 income tax expense was RMB25.1 million (US$3.4 million), representing an effective tax rate of 14.0% compared to 6.6% effective tax rate in the third quarter 2006, or an increase of 289.2% from the third quarter 2006. GAAP net income for the first nine months of 2007 was RMB433.7 million (US$57.9 million) compared to RMB255.8 million in same period of 2006, a year-over-year increase of 69.5%.

Third quarter 2007 basic and diluted non-GAAP earnings per share were RMB1.61 (US$0.22) and RMB1.52 (US$0.20), respectively. Third quarter 2007 GAAP basic and diluted earnings per share for the quarter were RMB1.45 (US$0.19) and RMB1.37 (US$0.18), respectively. Shares used in the computation of diluted earnings per share increased from 96.9 million in the third quarter 2006 to 113.0 million in the third quarter 2007 due to issuances of new shares and grants of share options in the past twelve months.

On March 16, 2007, the 10th People's Congress of China passed the China Unified Corporate Income Tax Law (the "New Law"), which will become effective on January 1, 2008. The New Law establishes a single unified 25% income tax rate for most companies with some preferential income tax rates to be applicable to qualified hi-tech enterprises. The related detailed implementation rules and regulations (the "IRRs") on the definition of various terms and the interpretation and application of the provisions of the New Law are expected to be promulgated by the State Council within 2007. The company currently believes that the new laws do not impact its qualification as a hi- tech enterprise, and as such, believe the current tax rate of 15% will continue to apply. In the event the promulgation of the new IRRs results in a change such that the company will no longer qualify as a hi-tech enterprise, it will be required to adjust certain long term deferred tax liabilities which will result in a loss in the period the change takes effect. If the company were to have applied a 25% tax rate in the third quarter 2007 an additional provision for income taxes of approximately RMB13.1 million (or RMB0.12 per diluted share) would have been recorded, based on the balance of the deferred tax liabilities as of March 31, 2007.

Other Select Data

Average account receivable days outstanding was 22 days in the third quarter 2007 compared to 20 days in the third quarter 2006. Inventory turnover was 64 days in the third quarter 2007 compared to 70 days in the third quarter 2006. Average account payable days outstanding was 57 days in the third quarter 2007 compared to 59 days in the third quarter 2006.

As of September 30, 2007, the company had RMB1,737 million (US$231.8 million) in cash and cash equivalents and short-term investments. Net cash generated from operating activities and capital expenditures in the first nine months of 2007 were RMB417.6 million (US$55.7 million) and RMB165.3 million (US$22.1 million), respectively.

As of September 30, 2007 the company had 3,541 employees compared to 3,260 employees on June 30, 2007.

Business Outlook for Full Year 2007

The company maintains its full-year 2007 net revenue guidance range of RMB2,155 million to RMB2,185 million, representing annual growth of 42% to 44% over full fiscal year 2006.

The company also maintains its full-year 2007 non-GAAP net income guidance range of RMB600 million to RMB630 million, representing annual growth of 44% to 51% over full fiscal year 2006.

Non-GAAP net income per share is expected to be in the range of RMB5.31 to RMB5.58 on a fully diluted basis, assuming an estimated diluted share count of 113 million.

The company estimates its total share-based compensation expenses in 2007 will be approximately RMB60 million to RMB64 million based on the employee share options that have been granted as of November 1, 2007. This estimate is subject to the finalization of the option pricing model used to estimate the fair value of the options recently granted. Total expense and/or amortization of intangible assets related to the April 2006 acquisition of minority interest will be approximately RMB18.8 million in 2007.

The company expects its updated capital expenditure for 2007 to be in the range of RMB350 million to RMB400 million from the previous range of RMB400 million to RMB480 million.

The company's practice is to provide guidance on a full year basis only. This forecast reflects Mindray's current and preliminary views, which are subject to change.

Other Developments

Mr. Xu Hang, Mindray's chairman and co-chief executive officer and Mr. Li Xiting, Mindray's president and co-chief executive officer, have both recently entered into "10b5-1" selling plans to sell a portion of their shares according to price and volume conditions.

Conference Call Information

Mindray's management will hold its third quarter 2007 earnings conference call on November 1, 2007 at 8:00 PM U.S. Eastern Time (8:00 AM on November 2, 2007 Beijing/Hong Kong Time).

Dial-in details for the earnings conference call are as follows:

Hong Kong: +852-3002-1672

U.S. Toll Free: +1-800-299-7089

International: +1-617-801-9714

Passcode for all regions: Mindray

A replay of the conference call may be accessed by phone at the following numbers until November 12, 2007.

U.S. Toll Free: +1-888-286-8010

International: +1-617-801-6888

Passcode: 18596098

A live and archived webcast of this conference call will be available on the Investor Relations section of Mindray's website at http://www.mindray.com .

About Mindray

Mindray Medical International Limited is a leading developer, manufacturer and marketer of medical devices in China with a significant and growing presence worldwide. Established in 1991, Mindray offers a broad range of products across three primary business segments: patient monitoring devices, diagnostic laboratory instruments, and ultrasound imaging systems. Mindray is headquartered in Shenzhen, China, and has 29 local sales and service offices in China, as well as sales and service offices in Amsterdam, Boston, Istanbul, London, Mexico City, Mumbai, Sao Paulo, Seattle, Toronto and Vancouver. For more information, please visit http://www.mindray.com .

Use of Non-GAAP Financial Measures

The company has reported for the third quarter 2007 and provided estimates for full year 2007 net income, operating income, or earning per share on a non-GAAP basis. Each of the terms as used by the company is defined as follows:

-- Non-GAAP gross profit represents gross profit reported in accordance

with GAAP, adjusted for the effects of share-based compensation, and

expense and/or amortization of acquired intangible assets.

-- Non-GAAP operating profit represents operating profit reported in

accordance with GAAP, adjusted for the effects of share-based

compensation, and expense and/or amortization of acquired intangible

assets including, but not limited to, in-progress research and

development (IPR&D).

-- Non-GAAP net income represents net income reported in accordance with

GAAP, adjusted for the effects of share-based compensation, and expense

and/or amortization of acquired intangible assets including, but not

limited to, IPR&D, all net of related tax impact.

-- Non-GAAP earnings per share represents non-GAAP net income divided by

the number of shares used in computing basic and diluted earnings per

share in accordance with GAAP, and excludes the impact of the deemed

dividends for the basic calculation.

In addition to Mindray's consolidated financial results under GAAP, the company also provides non-GAAP financial measures, including non-GAAP gross margin, non-GAAP operating profit, non-GAAP net income and non-GAAP earnings per share on a basic and fully diluted basis. The company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing Mindray's financial performance and liquidity and when planning and forecasting future periods. These non-GAAP operating measures are useful for understanding and assessing Mindray's underlying business performance and operating trends and the company expects to report operating profit and net income on a non-GAAP basis using a consistent method on a quarterly basis going forward.

The company computes its non-GAAP financial measures using the same consistent method from quarter to quarter. The company notes that these measures may
'/>"/>

SOURCE Mindray Medical International Limited
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Barriers will not stop convergence of medical technologies
3. Medical College team creates website for tracking flu
4. Biomedical engineering conference invites manufacturers
5. Visions: Wade offers straight talk on e-medical records
6. Merge unveils updated medical imaging software
7. Medical College receives $1.4M cancer grant
8. Medical technology firm lands $100K federal grant
9. Doyle outlines spending for Medical College, UWM
10. And the winners in medical design are
11. Manufacturing partnership will move into biotech and biomedical spaces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare Medical, LLC reports the ... Sonalink™ remote monitoring. The inaugural launch of this new technology occurred over the ... Samuel Peretsman to a HIFU technical expert at SonaCare Medical headquarters. , ...
(Date:2/10/2016)... Miami, FL (PRWEB) , ... February 10, 2016 ... ... leader in regenerative medicine, has announced a new agreement with Singapore-based Global Stem ... qualified physicians from the Philippines, Thailand and Singapore in the latest adipose and ...
(Date:2/9/2016)... ... February 09, 2016 , ... With a presidential election in November and the ... will bring together over 500 top healthcare leaders for a night and day of ... organized by MBA students of the University of Pennsylvania’s Wharton School, will be held ...
(Date:2/9/2016)... ... 08, 2016 , ... Net-Translators, an industry-leading provider of translation, ... revamped and improved website. In an on-going effort to further educate customers and ... communicate how the company designs and delivers thorough, high-quality results for its growing ...
Breaking Biology Technology:
(Date:2/4/2016)... , Feb. 4, 2016 The ... apparently one of the most popular hubs of ... MetaHIT and other huge studies of human microbiota, ... past few years, the microbiome space has literally ... biomedical research. This report focuses on biomedical ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS devices ... primarily focused on medical screening and diagnostic ... parameters. Wearable devices that facilitate and assure ... of movement are being bolstered through new ... biomedical signal acquisition coupled with wireless connectivity ...
(Date:2/2/2016)... 2016  Based on its recent analysis of ... US-based Intelligent Retinal Imaging Systems (IRIS) with the ... New Product Innovation. IRIS, a prominent cloud-based retinal ... , is poised to set the new ... market. The IRIS technology presents superior price-performance value ...
Breaking Biology News(10 mins):